A Prospective, Observational Study to Assess the Virological Response at Week 4 to the Therapy With PEGASYS® (Peginterferon Alfa 2a) Plus COPEGUS® (Ribavirin) in a Population of Treatment Naïve Patients With Chronic Hepatitis C, Genotype 2 or 3.
Phase of Trial: Phase IV
Latest Information Update: 28 Jun 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms POTENTE
- Sponsors Roche
- 12 May 2016 Protocol has been amended to change in study design from open label study to observational study.
- 21 May 2012 Actual end date May 2012 added as reported by ClinicalTrials.gov.
- 17 Jan 2012 Actual patient number changed from 249 to 271 as reported by ClinicalTrials.gov.